| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
NEW APPROACHES TO THE TREATMENT OF HEPATIC MALIGNANCIES |
From Winship Cancer Institute (GWC, DRM, CAS, AH, CC), Emory University School of Medicine; and Department of Biostatistics (RHL), Rollins School of Public Health, Emory University, Atlanta, Georgia.
Correspondence: Address correspondence and reprint requests to: Grant W. Carlson, MD, Winship Clinic, 1365B Clifton Road, Atlanta, GA 30322; Fax: 404-778-4255; E-mail: grant_carlson{at}emory.org
ABSTRACT
Background: The amount of metastatic disease in the sentinel lymph node (SLN) is examined as a prognostic factor in malignant melanoma.
Methods: SLN mapping was performed on 592 patients with stage I and II malignant melanoma from March 1, 1994, through December 31, 1999. One hundred four patients were found to have 134 sentinel SLNs containing metastatic melanoma. The slides were reviewed, and the size of the metastatic melanoma in each SLN was measured. The size of the metastatic deposit was defined as macrometastasis (>2 mm), micrometastasis (
2 mm), a cluster of cells (10–30 grouped cells) in the subcapsular space or interfollicular zone, or isolated melanoma cells (1 to 
20 individual cells) in subcapsular sinuses.
Results: The number of metastases in each SLN was isolated melanoma cells, n = 5 (3.7%); cluster of cells, n = 35 (26.1%); 2 mm, n = 45 (33.6%); and >2 mm, n = 49 (36.7%). Seventy-nine patients (76%) had a single positive SLN. The size of the largest nodal metastasis was used to stratify patients with multiple positive SLNs. The overall 3-year survival for patients with SLN micrometastases was 90%, versus 58% for patients with SLN macrometastases (P = .004).
Conclusions: The amount of metastatic melanoma in an SLN is an independent predictor of survival. Patients with SLN metastatic deposits >2 mm in diameter have significantly decreased survival.
Key Words: Sentinel lymph node • Melanoma • Metastatic disease • Prognosis
This article has been cited by other articles:
 |
|
 |
|
  C. Ariyan, M. S. Brady, M. Gonen, K. Busam, and D. Coit Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma Ann. Surg. Oncol., January 1, 2009; 16(1): 186 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gershenwald, R. H.I. Andtbacka, V. G. Prieto, M. M. Johnson, A. H. Diwan, J. E. Lee, P. F. Mansfield, J. N. Cormier, C. W. Schacherer, and M. I. Ross Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma J. Clin. Oncol., September 10, 2008; 26(26): 4296 - 4303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Frankel, K. A. Griffith, L. Lowe, S. L. Wong, C. K. Bichakjian, A. E. Chang, V. M. Cimmino, C. R. Bradford, R. S. Rees, T. M Johnson, et al. Do Micromorphometric Features of Metastatic Deposits Within Sentinel Nodes Predict Nonsentinel Lymph Node Involvement in Melanoma? Ann. Surg. Oncol., September 1, 2008; 15(9): 2403 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. I. Nowecki, P. Rutkowski, and W. Michej The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2-pT3) Ann. Surg. Oncol., August 1, 2008; 15(8): 2223 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Satzger, B. Volker, A. Meier, A. Kapp, and R. Gutzmer Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes Ann. Surg. Oncol., June 1, 2008; 15(6): 1723 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Riber-Hansen, P. Sjoegren, S. J. Hamilton-Dutoit, and T. Steiniche Extensive Pathological Analysis of Selected Melanoma Sentinel Lymph Nodes: High Metastasis Detection Rates at Reduced Workload Ann. Surg. Oncol., May 1, 2008; 15(5): 1492 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Rossi, G. L. De Salvo, E. Bonandini, S. Mocellin, M. Foletto, S. Pasquali, P. Pilati, M. Lise, D. Nitti, E. Rizzo, et al. Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node Ann. Surg. Oncol., April 1, 2008; 15(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Koskivuo, L. Talve, P. Vihinen, M. Maki, T. Vahlberg, and E. Suominen Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Case-Control Study Ann. Surg. Oncol., December 1, 2007; 14(12): 3566 - 3574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Govindarajan, D. M. Ghazarian, D. R. McCready, and W. L. Leong Histological Features of Melanoma Sentinel Lymph Node Metastases Associated with Status of the Completion Lymphadenectomy and Rate of Subsequent Relapse Ann. Surg. Oncol., February 1, 2007; 14(2): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. van Akkooi, J. de Wilt, C Verhoef, P. Schmitz, A. van Geel, A. Eggermont, and M Kliffen Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann. Onc., October 1, 2006; 17(10): 1578 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Thomas Time to Re-Evaluate Sentinel Node Biopsy in Melanoma Post-Multicenter Selective Lymphadenectomy Trial J. Clin. Oncol., December 20, 2005; 23(36): 9443 - 9444. [Full Text] [PDF]
|
|
|
|
|
|
A. Romanini, G. Manca, D. Pellegrino, R. Murr, S. Sarti, F. Bianchi, A. AlSharif, C. Orlandini, V. Zucchi, M. Castagna, et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome Ann. Onc., November 1, 2005; 16(11): 1832 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Pawlik, M. I. Ross, M. M. Johnson, C. W. Schacherer, D. M. McClain, P. F. Mansfield, J. E. Lee, J. N. Cormier, and J. E. Gershenwald Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy Ann. Surg. Oncol., August 1, 2005; 12(8): 587 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Starritt, R. F. Uren, R. A. Scolyer, M. J. Quinn, and J. F. Thompson Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma Ann. Surg. Oncol., January 1, 2005; 12(1): 18 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsao, M. B. Atkins, and A. J. Sober Management of Cutaneous Melanoma N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012. [Full Text] [PDF]
|
|
|
|
|
|
K. M. McMasters Editorial: What Good is Sentinel Lymph Node Biopsy for Melanoma if it does not Improve Survival? Ann. Surg. Oncol., September 1, 2004; 11(9): 810 - 812. [Full Text] [PDF]
|
|
|
|
|
|
D.J. Dewar, B. Newell, M.A. Green, A.P. Topping, B.W.E.M. Powell, and M.G. Cook The Microanatomic Location of Metastatic Melanoma in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement J. Clin. Oncol., August 15, 2004; 22(16): 3345 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R Kell and M. J Kerin Sentinel lymph node biopsy BMJ, June 5, 2004; 328(7452): 1330 - 1331. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takeuchi, A. Fujimoto, M. Tanaka, T. Yamano, E. Hsueh, and D. S. B. Hoon CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2351 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Carlson Editorial: Age and the Incidence of Sentinel Lymph Node Metastases in Melanoma Ann. Surg. Oncol., March 1, 2004; 11(3): 236 - 237. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
